亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Identifying Beneficiaries of Bailout Intracranial Angioplasty or Stenting Following Thrombectomy: A Secondary Analysis of the ANGEL-REBOOT Trial

医学 血管成形术 改良兰金量表 闭塞 优势比 随机对照试验 冲程(发动机) 耐火材料(行星科学) 子群分析 人口 狭窄 外科 内科学 血管内治疗 溶栓 心脏病学 临床终点 临床试验 单中心 急性中风 中期分析 可能性 紧急援助
作者
Lei Li,Yingchun Wu,Chenghua Xu,Haoquan Sun,Shen Qu,Qi Wu,Xingkai Yang,Z Peng,Ling Song,Guangming Yang,Qinglin Bao,Shan Ping Yu,Feng Gao
出处
期刊:American Journal of Neuroradiology [American Society of Neuroradiology]
卷期号:: ajnr.A9341-ajnr.A9341 被引量:1
标识
DOI:10.3174/ajnr.a9341
摘要

BACKGROUND AND PURPOSE: The Randomized Trial of Bailout Intracranial Angioplasty or Stenting Following Thrombectomy for Acute Large Vessel Occlusion (ANGEL-REBOOT) demonstrated no overall benefit from bailout angioplasty or stenting (BAOS) following thrombectomy for acute large-vessel occlusion. Nonetheless, the heterogeneous patient population suggests potential subgroup benefits. We aimed to identify the specific subgroups that may benefit from BAOS after thrombectomy for acute large-vessel occlusion. MATERIALS AND METHODS: This is a secondary analysis of the ANGEL-REBOOT trial, a multicenter randomized controlled trial conducted in China from December 2021 to March 2023, which included participants with large-vessel occlusion within 24 hours of symptom onset who had unsuccessful recanalization or >70% residual stenosis after thrombectomy. Participants were stratified into three subgroups: (1) refractory occlusion, (2) intracranial atherosclerotic-related large-vessel occlusion with unsuccessful recanalization (ICAS-LVO-UR) after thrombectomy, and (3) ICAS-LVO with successful recanalization (ICAS-LVO-SR) after thrombectomy. Efficacy and safety outcomes were assessed in the short term (90 days) and long term (1 year). RESULTS: A total of 347 participants were included in this secondary analysis and divided into three subgroups: refractory occlusion (n=20), ICAS-LVO-UR (n=95), and ICAS-LVO-SR (n=232). For short-term efficacy, the refractory occlusion subgroup showed worse 90-day modified Rankin Scale (mRS) outcomes with BAOS versus standard therapy (common odds ratio [OR], 0.14 [95% CI, 0.02-0.81]); the ICAS-LVO-SR and ICAS-LVO-UR subgroups showed favorable and unfavorable trends, respectively. In the long-term, BAOS significantly improved the 1-year outcomes in the ICAS-LVO-SR subgroup: better mRS distribution (generalized OR, 1.72 [95% CI, 1.07-2.77]), higher functional independence (OR, 2.80 [95% CI, 1.59-4.92]), and reduced target-vessel stroke recurrence (hazard ratios [HR], 0.25 [95% CI, 0.08-0.75]). No significant long-term findings were observed in the other two subgroups. Safety outcomes were comparable between the BAOS and standard therapy groups across all subgroups. CONCLUSIONS: In this secondary analysis of the ANGEL-REBOOT trial, BAOS was associated with improved 1-year outcomes in patients with successful recanalization (eTICI ≥2b) but residual severe stenosis (≥70%) after thrombectomy. Given the inherent limitations of this analysis, these findings should be interpreted as hypothesis-generating and warrant confirmation in future large-scale prospective trials.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
2秒前
开朗的千雁完成签到 ,获得积分10
3秒前
weako发布了新的文献求助10
4秒前
斯文败类的应助被开心的中心采纳,获得10
5秒前
369ninja发布了新的文献求助10
8秒前
辛勤元芹发布了新的文献求助10
8秒前
hgl完成签到,获得积分10
8秒前
stooyan的应助被王星晓采纳,获得100
9秒前
9秒前
wanci的应助被Clearday采纳,获得10
10秒前
10秒前
自由滑大王完成签到 ,获得积分10
14秒前
酷炫如曼完成签到,获得积分10
15秒前
烨无殇完成签到,获得积分10
15秒前
Anla完成签到,获得积分10
19秒前
21秒前
22秒前
agnway完成签到,获得积分10
24秒前
搞怪的老九的应助被涵泽采纳,获得10
24秒前
lidocaine完成签到 ,获得积分10
25秒前
para完成签到,获得积分10
27秒前
肖肖发布了新的文献求助10
27秒前
xi完成签到 ,获得积分10
27秒前
28秒前
山茶花开完成签到,获得积分10
28秒前
希望天下0贩的0的应助被Sissi采纳,获得10
28秒前
欢呼凝海完成签到 ,获得积分10
31秒前
科研通AI2S的应助被神勇的筝采纳,获得30
31秒前
zzjj完成签到 ,获得积分10
33秒前
36秒前
38秒前
39秒前
maki完成签到,获得积分10
42秒前
q2026完成签到 ,获得积分20
42秒前
123完成签到,获得积分10
43秒前
缓慢的秋荷完成签到,获得积分10
43秒前
Laluna的应助被suicone采纳,获得10
44秒前
巨型肥猫发布了新的文献求助10
44秒前
48秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179656
求助须知:如何正确求助?哪些是违规求助? 9569921
关于积分的说明 21807706
捐赠科研通 7775141
什么是DOI,文献DOI怎么找? 3433072
关于科研通互助平台的介绍 2557032
邀请新用户注册赠送积分活动 2478778